Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Notch Therapeutics is a biotechnology company focused on developing and commercializing a pipeline of allogeneic, off-the-shelf, T cell therapies derived from induced pluripotent stem cells (iPSCs) for the treatment of cancer and other diseases. Their proprietary Engineered Thymic Niche (ETN™) platform recreates key aspects of thymic T cell development to generate T cells with desired therapeutic properties. Notch aims to deliver scalable, consistent, and cost-effective cell therapies.
Serves as the main corporate office, housing executive leadership, core research and development activities, and administrative functions.
Located in a modern office building in downtown Vancouver, providing access to advanced laboratory facilities and a vibrant biotech ecosystem.
Characterized by a highly collaborative, innovative, and science-driven environment. Employees are typically passionate about advancing cell therapy and making an impact on patient lives. The culture emphasizes teamwork, scientific rigor, and a fast-paced approach typical of a growing biotech.
The Vancouver HQ is central to Notch's strategic direction, pioneering research in iPSC-derived T cell therapies, and fostering collaborations within Canada's life sciences hub.
Notch Therapeutics currently has a significant presence in North America, with key operational sites in Vancouver and Toronto, Canada, and Seattle, USA. These locations support the company's end-to-end capabilities, from foundational research and discovery to process development, manufacturing, and clinical trial planning. While current operations are North America-centric, their ambition to provide global 'off-the-shelf' therapies implies future expansion to support international clinical trials and commercialization.
410 West Georgia Street, Suite 1700
Vancouver
British Columbia
Canada
Address: 2401 Elliott Avenue, Suite 400, Seattle, WA 98121, USA
To establish robust and scalable manufacturing processes for their allogeneic cell therapy candidates and to facilitate US-based clinical operations and collaborations.
Address: MaRS Centre, West Tower, 661 University Ave., Suite 465, Toronto, ON M5G 1M1, Canada
To drive innovation in iPSC differentiation and T cell engineering, and to foster strategic partnerships within one of Canada's largest biomedical research clusters.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Notch Therapeutics' leadership includes:
Notch Therapeutics has been backed by several prominent investors over the years, including:
In the past 12-15 months, Notch Therapeutics has made significant additions to its executive team, notably appointing a new Chief Financial Officer and Chief Medical Officer. No major executive departures have been publicly announced during this specific 12-month window.
Discover the tools Notch Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Notch Therapeutics likely uses common corporate email formats. The most probable formats are [first_initial][last]@notchtx.com or [first].[last]@notchtx.com.
[f][last]@notchtx.com or [first].[last]@notchtx.com
Format
jdoe@notchtx.com or jane.doe@notchtx.com
Example
80%
Success rate
Business Wire • November 2, 2023
Notch Therapeutics shared promising preclinical data for its iPSC-derived gamma delta (γδ) T cell candidates at the Society for Immunotherapy of Cancer (SITC) 2023. The data highlighted the ETN™ platform's ability to generate γδ T cells with potent anti-tumor activity....more
Business Wire • April 18, 2023
Notch Therapeutics announced the appointment of Kam Fanaian as Chief Financial Officer and David Shook, M.D., as Chief Medical Officer. These appointments aim to bolster the company's leadership as it advances its pipeline....more
Business Wire • October 26, 2022
Allogene and Notch entered an exclusive collaboration to develop and commercialize iPSC-derived AlloCAR T™ therapies for initial targets in hematologic malignancies. Notch received an upfront payment and is eligible for milestones and royalties....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Notch Therapeutics, are just a search away.